Three of the most important targeted therapies used in the clinic are vemurafenib, trametinib, dabrafenib and some of their combinations, which are FDA approved regimens for melanoma treatment acting by blocking BRAF with activatory mutations, such as V600E or V600K. Here, BRAF is linked to melanoma.